RE
REGN.US Regeneron Pharmaceuticals Inc
- Market cap
- USD 99.1B
- P/E
- 21.2x
- P/B
- 2.94x
- ROE
- 15.8%
- Dividend yield
- 0.37%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is REGN.US undervalued?
Graham numberREGN.US trades 66.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regeneron Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Regeneron Pharmaceuticals Inc yet.
Regeneron Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic r…
Full company profileRegeneron Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regeneron Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.86B | 5.87B | 6.71B | 7.86B | 8.50B | 16.1B | 12.2B | 13.1B | 14.2B | 14.3B | 17.3B |
| Gross Profit | 4.56B | 5.48B | 6.28B | 7.08B | 7.14B | 13.3B | 10.5B | 12.2B | 12.2B | 12.2B | 14.9B |
| Operating Income | 1.33B | 2.08B | 2.53B | 2.21B | 3.58B | 8.95B | 4.74B | 4.05B | 3.99B | 3.58B | 5.31B |
| EBITDA | 1.44B | 2.23B | 2.68B | 2.42B | 4.10B | 9.67B | 5.26B | 4.05B | 5.32B | 5.82B | 6.48B |
| Net Income | 896M | 1.20B | 2.44B | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B | 4.41B | 4.50B | 5.30B |
| EPS | 7.70 | 10 | 21 | 18 | 31 | 72 | 38 | 35 | 38 | 41 | 50 |
| Balance Sheet | |||||||||||
| Total Assets | 6.97B | 8.76B | 11.7B | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 37.8B | 40.6B | 44.4B |
| Total Liabilities | 2.52B | 2.62B | 2.98B | 3.72B | 6.14B | 6.67B | 6.55B | 7.11B | 8.41B | 9.30B | 10.9B |
| Shareholders' Equity | 4.45B | 6.14B | 8.76B | 11.1B | 11.0B | 18.8B | 22.7B | 26.0B | 29.4B | 31.3B | 33.5B |
| Cash & Short-term Investments | 1.04B | 2.90B | 4.56B | 3.21B | 6.72B | 5.69B | 7.74B | 10.8B | 9.01B | 8.61B | 9.30B |
| Total Debt | 481M | 1.17B | 799M | 714M | 3.61B | 2.70B | 2.70B | 2.70B | 2.70B | 2.71B | 2.71B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.49B | 1.31B | 2.20B | 2.43B | 2.62B | 7.08B | 5.01B | 4.59B | 4.42B | 4.98B | 4.90B |
| Capital Expenditure | 512M | 273M | 383M | 430M | 615M | 552M | 590M | 719M | 756M | 898M | 1.03B |
| Free Cash Flow | 974M | 1.03B | 1.81B | 2.00B | 2.00B | 6.53B | 4.42B | 3.88B | 3.66B | 4.08B | 3.87B |
| Ratios | |||||||||||
| ROE | 20.1% | 19.5% | 27.9% | 19.1% | 31.9% | 43.0% | 19.1% | 15.2% | 15.0% | 14.4% | 15.8% |
| ROA | 12.8% | 13.7% | 20.8% | 14.3% | 20.5% | 31.7% | 14.9% | 12.0% | 11.7% | 11.1% | 11.9% |
| Net Profit Margin | 18.4% | 20.4% | 36.4% | 26.9% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% | 30.5% |
| Debt to Equity | 0.11x | 0.19x | 0.09x | 0.06x | 0.33x | 0.14x | 0.12x | 0.10x | 0.09x | 0.09x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Regeneron Pharmaceuticals Inc dividends
- Dividend yield
- 0.37%
- Forward dividend
- 3.76 USD
- Payout ratio
- 8.2%
- Ex-dividend date
- Nov 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 370M | 3.41 | 8.2% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 359M | 3.09 | 29.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Regeneron Pharmaceuticals Inc
- Insiders 2.15%
- Institutions 92.17%
- Public & others 5.69%
- Shares outstanding 102M
- Free float 96.3M
Top funds holding REGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.21M | 3.10% | -1.92% | Sep 2026 |
| Dodge & Cox Stock I | 3.09M | 2.99% | -1.06% | Sep 2026 |
| Vanguard 500 Index Investor | 2.57M | 2.49% | -2.99% | Sep 2026 |
| Invesco QQQ Trust | 2.10M | 2.03% | -0.10% | Oct 2026 |
| iShares Core S&P 500 ETF | 1.31M | 1.26% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 1.27M | 1.23% | -1.77% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 1.19M | 1.15% | -0.25% | Oct 2026 |
| Putnam Large Cap Value A | 1.15M | 1.11% | 0.00% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 1.08M | 1.05% | -2.81% | Sep 2026 |
| Vanguard Health Care Inv | 1.02M | 0.99% | -1.02% | Sep 2026 |
| Vanguard MStar Value Index Investor | 963K | 0.93% | -2.23% | Sep 2026 |
| iShares Biotechnology ETF | 771K | 0.75% | -0.31% | Oct 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 717K | 0.69% | +0.87% | Oct 2026 |
| CREF Total Global Stock Account R3 | 708K | 0.68% | +0.24% | Sep 2026 |
| CREF Growth R3 | 587K | 0.57% | +8.92% | Sep 2026 |
| JPMorgan Equity Premium Income ETF | 549K | 0.53% | -0.02% | Oct 2026 |
| First Trust Rising Dividend Achiev ETF | 519K | 0.50% | 0.00% | Oct 2026 |
| Vanguard Institutional Index I | 519K | 0.50% | -2.91% | Sep 2026 |
| Invesco NASDAQ 100 ETF | 481K | 0.47% | +0.15% | Oct 2026 |
| American Funds New Perspective A | 468K | 0.45% | 0.00% | Sep 2026 |
Top institutions holding REGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 9.11M | 8.81% | +1.85% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.63M | 6.41% | -0.38% | Jun 2026 |
| Dodge & Cox | 4.87M | 4.71% | +9.26% | Jun 2026 |
| State Street Corp | 4.83M | 4.67% | +3.65% | Jun 2026 |
| Amvescap Plc. | 3.94M | 3.81% | +0.91% | Jun 2026 |
| JPMorgan Chase & Co | 3.77M | 3.65% | -12.47% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.18M | 3.07% | +84.53% | Jun 2026 |
| Franklin Templeton Inc | 2.77M | 2.68% | +1.83% | Jun 2026 |
| Geode Capital Management, LLC | 2.63M | 2.54% | +0.69% | Jun 2026 |
| Nuveen, LLC | 2.02M | 1.95% | -2.18% | Jun 2026 |
| Loomis, Sayles & Company LP | 1.86M | 1.80% | -2.78% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.53M | 1.48% | -29.75% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.40M | 1.35% | +5.94% | Jun 2026 |
| Bank of America Corp | 1.29M | 1.25% | +8.53% | Jun 2026 |
| Wellington Management Company LLP | 1.27M | 1.23% | -30.88% | Jun 2026 |
| NORGES BANK | 1.17M | 1.13% | -10.57% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.16M | 1.12% | -10.56% | Jun 2026 |
| AQR Capital Management LLC | 1.13M | 1.09% | -8.52% | Jun 2026 |
| Amundi | 1.01M | 0.98% | +0.37% | Jun 2026 |
| Northern Trust Corp | 916K | 0.89% | -2.70% | Jun 2026 |
Regeneron Pharmaceuticals Inc company profile
- Company name
- Regeneron Pharmaceuticals Inc
- Ticker
- REGN.US
- Exchange
- USA Stocks
- Listed since
- Apr 2, 1991
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15,410
- Fiscal year end
- December
- Address
- 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
- Phone
- 914 847 7000
- Website
- regeneron.com
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals Inc management
10- Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, CEO & Co-Chairman · born 1953
- Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman · born 1960
- Mr. Christopher R. Fenimore CPAExecutive VP of Finance & CFO · born 1971
- Mr. Joseph J. LaRosa J.D.Executive VP, General Counsel & Secretary · born 1959
- Dr. Andrew J. Murphy Ph.D.Executive VP of Research & Co-Chief Scientific Officer · born 1958
- Mr. Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply · born 1973
- Mr. Rajesh AhujaSenior Vice President of Quality Assurance & Operations
- Mr. Ryan SteinbergerExecutive VP, Chief Digital & Technology Officer
- Mr. Ryan CroweSenior Vice President of Investor Relations & Strategic Analysis
- Ms. Melissa LoznerSenior VP & Chief Compliance Officer